Nexel

NEXEL Co., Ltd. is a biotechnology company specializing in induced pluripotent stem cell (iPSC) technology. It was founded in 2012 by CEO Choongseong Han and spun off from Korea University's School of Life Sciences. The company is headquartered in Seoul, South Korea.

NEXEL develops and commercializes iPSC-derived cell products that mimic human functionality, providing researchers with advanced tools for drug screening, toxicity testing, and disease modeling. Its primary products include iPSC-derived cardiomyocytes (Cardiosight®-S), hepatocytes (Hepatosight®-S), and neurons (Neurosight®-S). These products are designed to offer more accurate and human-relevant data compared to traditional animal testing methods. The company also offers a cardiac safety screening service called NeXST, which utilizes its cardiomyocyte technology to predict cardiotoxicity early in the drug development process. In addition to its cell products, NEXEL provides custom CDMO services, including iPSC reprogramming and customized cell production.

The company is also engaged in new drug development, leveraging its stem cell expertise to discover protein-based therapies. Its lead drug candidate, NP-011, is a first-in-class anti-fibrotic protein being developed for conditions such as liver, heart, and lung diseases. NEXEL has raised approximately $27 million in funding over two rounds, with its Series B round concluding in April 2021.

Keywords: iPSC technology, human induced pluripotent stem cells, drug screening, toxicity testing, cardiomyocytes, hepatocytes, neurons, cardiac safety services, disease modeling, cell therapy, anti-fibrotic drug development, organoids, drug discovery, in-vitro testing, CDMO, stem cell research, regenerative medicine, biotechnology, non-animal testing, toxicology.